A Tumor Growth Inhibition Model Based on M‐Protein Levels in Subjects With Relapsed/Refractory Multiple Myeloma Following Single‐Agent Carfilzomib Use
Open Access
- 20 November 2015
- journal article
- research article
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 4 (12) , 711-719
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- PKPD Modeling of VEGF, sVEGFR‐2, sVEGFR‐3, and sKIT as Predictors of Tumor Dynamics and Overall Survival Following Sunitinib Treatment in GISTCPT: Pharmacometrics & Systems Pharmacology, 2013
- Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safetyLeukemia, 2013
- Cancer statistics, 2013CA: A Cancer Journal for Clinicians, 2013
- An open‐label, single‐arm, phase 2 study of single‐agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomibBritish Journal of Haematology, 2012
- An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myelomaBlood, 2012
- Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse EventsClinical Cancer Research, 2011
- Model-Based Prediction of Phase III Overall Survival in Colorectal Cancer on the Basis of Phase II Tumor DynamicsJournal of Clinical Oncology, 2009
- Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myelomaBlood, 2007
- International uniform response criteria for multiple myelomaLeukemia, 2006
- Perl-speaks-NONMEM (PsN)—a Perl module for NONMEM related programmingComputer Methods and Programs in Biomedicine, 2004